Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study

被引:14
作者
Kridin, Khalaf [1 ]
Pam, Nadav [1 ]
Bergman, Reuven [1 ,2 ]
Khamaysi, Ziad [1 ,2 ]
机构
[1] Rambam Hlth Care Campus, Dept Dermatol, POB 9602, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel
关键词
infantile hemangioma; late infancy; postproliferative; propranolol; UNTREATED HEMANGIOMAS; PHASE;
D O I
10.1111/dth.13331
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase. Evaluation of the effectiveness of oral propranolol is less established when it is administered in late infancy following the proliferative phase. We aimed to assess the clinical outcomes of pediatric patients managed by oral propranolol beyond the proliferative phase of IH. A retrospective cohort study in a tertiary health care referral center was conducted to track all patients with IH receiving systemic propranolol following the proliferative phase. Twenty-eight eligible patients were managed by 2 to 3 mg/kg per day of oral propranolol for IH beyond the proliferative phase, defined at 9 months of age. The mean age at the initiation of propranolol was estimated at 11.25 (SD 2.24) months. All eligible patients experienced some degree of clinical resolution, with the average improvement rate being estimated at 77.1% (SD 16.1). Comparable results were achieved among patients who were placed on propranolol at an age older than 12 months and those managed between the age of 9 and 12 months. No serious adverse events were observed during the follow-up duration. In conclusion, oral propranolol is a safe and effective treatment for patients with IH initiating this agent beyond the proliferative phase.
引用
收藏
页数:5
相关论文
共 17 条
  • [1] Assessment of Oral Propranolol Administration for Infantile Hemangioma in Oral and Maxillofacial Region Aided by Ultrasonography
    Al-Mahdi, Akmam H.
    Al-Sada, Milad A.
    [J]. JOURNAL OF CRANIOFACIAL SURGERY, 2020, 31 (01) : 189 - 192
  • [2] Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy
    Baselga, Eulalia
    Roe, Esther
    Coulie, Julien
    Munoz, Fania Z.
    Boon, Laurence M.
    McCuaig, Catherine
    Hernandez-Martin, Angela
    Gich, Ignasi
    Puig, Luis
    [J]. JAMA DERMATOLOGY, 2016, 152 (11) : 1239 - 1243
  • [3] Untreated Hemangiomas: Growth Pattern and Residual Lesions
    Bauland, Constantijn G.
    Luning, Thomas H.
    Smit, Jeroen M.
    Zeebregts, Clark J.
    Spauwen, Paul H. M.
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 127 (04) : 1643 - 1648
  • [4] When to stop propranolol for infantile hemangioma
    Chang, Lei
    Gu, Yifei
    Yu, Zhang
    Ying, Hanru
    Qiu, Yajing
    Ma, Gang
    Chen, Hui
    Jin, Yunbo
    Lin, Xiaoxi
    [J]. SCIENTIFIC REPORTS, 2017, 7 : 1 - 7
  • [5] Growth characteristics of infantile hemangiomas: Implications for management
    Chang, Linda C.
    Haggstrom, Anita N.
    Drolert, Beth A.
    Baselga, Eulalia
    Chamlin, Sarah L.
    Garzon, Maria C.
    Horii, Kimberly A.
    Lucky, Anne W.
    Mancini, Anthony J.
    Metry, Denise W.
    Nopper, Amy J.
    Frieden, Ilona J.
    [J]. PEDIATRICS, 2008, 122 (02) : 360 - 367
  • [6] Propranolol Induces Regression of Hemangioma Cells Through HIF-1α-Mediated Inhibition of VEGF-A
    Chim, Harvey
    Armijo, Bryan S.
    Miller, Erin
    Gliniak, Christy
    Serret, Marc A.
    Gosain, Arun K.
    [J]. ANNALS OF SURGERY, 2012, 256 (01) : 146 - 156
  • [7] Infantile Hemangioma: Clinical Assessment of the Involuting Phase and Implications for Management
    Couto, Rafael A.
    Maclellan, Reid A.
    Zurakowski, David
    Greene, Arin K.
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 2012, 130 (03) : 619 - 624
  • [8] Oral propranolol for infantile hemangiomas beyond the proliferative phase
    Kagami, Shinji
    Katori, Tatsuo
    [J]. JOURNAL OF DERMATOLOGY, 2018, 45 (10) : 1199 - 1202
  • [9] Clinical Practice Guideline for the Management of Infantile Hemangiomas
    Krowchuk, Daniel P.
    Frieden, Ilona J.
    Mancini, Anthony J.
    Darrow, David H.
    Blei, Francine
    Greene, Arin K.
    Annam, Aparna
    Baker, Cynthia N.
    Frommelt, Peter C.
    Hodak, Amy
    Pate, Brian M.
    Pelletier, Janice L.
    Sandrock, Deborah
    Weinberg, Stuart T.
    Whelan, Mary Anne
    [J]. PEDIATRICS, 2019, 143 (01)
  • [10] A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma
    Leaute-Labreze, C.
    Hoeger, P.
    Mazereeuw-Hautier, J.
    Guibaud, L.
    Baselga, E.
    Posiunas, G.
    Phillips, R. J.
    Caceres, H.
    Lopez Gutierrez, J. C.
    Ballona, R.
    Friedlander, S. F.
    Powell, J.
    Perek, D.
    Metz, B.
    Barbarot, S.
    Maruani, A.
    Szalai, Z. Z.
    Krol, A.
    Boccara, O.
    Foelster-Holst, R.
    Febrer Bosch, M. I.
    Su, J.
    Buckova, H.
    Torrelo, A.
    Cambazard, F.
    Grantzow, R.
    Wargon, O.
    Wyrzykowski, D.
    Roessler, J.
    Bernabeu-Wittel, J.
    Valencia, A. M.
    Przewratil, P.
    Glick, S.
    Pope, E.
    Birchall, N.
    Benjamin, L.
    Mancini, A. J.
    Vabres, P.
    Souteyrand, P.
    Frieden, I. J.
    Berul, C. I.
    Mehta, C. R.
    Prey, S.
    Boralevi, F.
    Morgan, C. C.
    Heritier, S.
    Delarue, A.
    Voisard, J-J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) : 735 - 746